What BioNTech did next: the plan for a revolution in cancer care | BioNTech能为癌症治疗带来一场革命吗? - manbetx20客户端下载
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持manbetx3.0 大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
17周年大视野精选
【高端限免】What BioNTech did next: the plan for a revolution in cancer care
BioNTech能为癌症治疗带来一场革命吗?

The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven | 这家德国公司正将新冠疫苗的利润投入肿瘤学领域,但其技术在很大程度上仍未得到验证。

Uğur Şahin arrives at BioNTech’s headquarters in the German city of Mainz on the same battered bicycle he has been riding for 20 years. Developing the best-selling Covid-19 vaccine may have transformed BioNTech’s founders into billionaires, but the chief executive of the biotech business has resisted making changes in his personal life.
乌尔·沙欣(Uğur Şahin)骑着他已经20岁高龄的破旧自行车来到位于德国美因茨市的BioNTech总部。开发最畅销的新冠疫苗可能使BioNTech的创始人变成了亿万富翁,但这家生物技术企业的首席执行官却抵制在个人生活中作出改变。
Şahin and his wife, chief medical officer Özlem Türeci, set up BioNTech in 2008 to create a toolbox to transform the treatment of cancer. Since finding fame, their vision has not shifted. When practising as doctors, the pair had become frustrated at the gap between the cancer drugs available on the wards — and what they believed was scientifically possible.
沙欣和他的妻子,首席医疗官奥兹莱姆•图雷西(Özlem Türeci),在2008年成立了BioNTech,创建了一个工具箱,以改变癌症的治疗。自从成名以来,他们的眼光并没有改变。在当医生的时候,面对病房里提供的癌症药物和他们认为在科学上可行的药物之间的差距,这对夫妇感到沮丧。
So, while the mRNA vaccine they developed with the American pharmaceuticals company Pfizer has saved millions of lives and brought economies around the world back to life, it was also, in some ways, a side hustle. BioNTech “is a cancer company that was able to drop everything they were doing to create a Covid vaccine,” says Akash Tewari, an analyst at Jefferies.
因此,尽管他们与美国辉瑞制药公司合作开发的mRNA疫苗拯救了数百万人的生命,并使世界各地的manbetx20客户端下载 恢复了活力,但在某些方面,这仍是一项副业。杰富瑞(Jefferies)的分析师阿卡什·特瓦里(Akash Tewari)说:BioNTech“是一家[研究]癌症的公司,能够放下他们正在做的一切来创造一种新冠疫苗”。
The decision to do so has brought an unprecedented windfall of cash to the company, which is now sitting on assets of €19bn, with billions more in revenue expected. That amount equates to “a lifetime of funding”, says Suzanne van Voorthuizen, co-head of life sciences securities at Dutch bank Kempen & Co.
这一决定为该公司带来了前所未有的现金横财,该公司目前坐拥190亿欧元资产,预计营收还将增加数十亿欧元。荷兰的银行Kempen & Co.生命科学证券部门联席主管苏珊娜•范•沃特伊森(Suzanne van Voorthuizen)表示,这笔资金相当于“够用一辈子”。
去年9月,法国生物制药公司Cellectis在巴黎的实验室里,实验室技术人员正在生产CAR-T细胞和RNA
While some billionaires use their wealth to buy newspapers or fund extraterrestrial adventures, Şahin and Türeci will use theirs to fuel their ambitious — though still nascent — plans in oncology. They are doubling down on a hope that Şahin admits once sounded like science fiction: to be able to tailor drugs to each patient’s cancer.
当一些亿万富翁用他们的财富购买报纸或资助外星探险时,沙欣和图雷西将用他们的财富来推动他们在肿瘤学方面的雄心勃勃的计划——尽管仍处于萌芽状态。他们正在加倍努力,实现沙欣承认曾经听起来像科幻小说的希望:能够为每个病人的癌症量身定做药物。
The company recently took steps in the right direction with two early stage trials showing promising data, one in pancreatic cancer and the other targeting solid tumours including ovarian and testicular cancer.
该公司最近朝着正确的方向采取了步骤,两项早期试验显示出了有希望的数据,一项针对胰腺癌,另一项针对包括卵巢癌和睾丸癌在内的实体肿瘤。
Success would mean a new journey: reimagining the whole pharmaceutical industry.
成功意味着一段新的旅程:重塑整个制药行业。
“We had this idea to develop technologies dedicated to really saving every single individual patient,” says Şahin. “Because every patient is different, and you can’t just take something off the shelf.”
沙欣说:“我们有这个想法,就是开发专门用于真正拯救每一位患者的技术。因为每个病人都是不同的,你不能一招鲜吃遍天。”

The Covid cash

新冠现金

Şahin wheels his bike around the perimeter of a huge hole on the plot of the company’s site — the foundation for a new 20,000 square foot building. Across from his office, a three-storey temporary lab in portacabins has popped up to press on with the mission right away: this year research and development spending at BioNTech is doubling to €1.5bn.
沙欣骑着自行车绕着公司地块上的一个巨大的洞口转了一圈,这是一座2万平方英尺的新建筑的地基。在他的办公室对面,一个三层楼高的临时实验室拔地而起,以便马上完成任务:今年BioNTech的研发支出将翻倍,达到15亿欧元。
Dropping his helmet in his office and donning a white coat, Şahin heads to the lab. Inside, a machine synthesises the DNA templates used to create messengerRNA, the technology BioNTech has helped to pioneer.
沙欣在办公室放下头盔,穿上白大褂,前往实验室。在实验室里,一台机器正在合成用于制造mRNA的DNA模板,这是BioNTech帮助开创的技术。
The mRNA acts as a set of instructions to cells, telling them to build certain proteins. The response to the pandemic proved for the first time that the technology could be used to create a highly effective vaccine: mRNA was deployed in a vaccine to help the immune system recognise and fight intruders such as the coronavirus Sars CoV-2. Next, BioNTech wants to use the code to prompt the body’s defences to tackle a tumour.
mRNA对细胞来说是一套指令,告诉它们要制造某些蛋白质。对新冠病毒大流行病的反应首次证明了该技术可用于创造高效的疫苗:mRNA被部署在疫苗中,帮助免疫系统识别和对抗冠状病毒Sars CoV-2等入侵者。接下来,BioNTech希望使用该代码来促使身体的防御系统对付肿瘤。
Yet, unlike its American rival Moderna, which is focused on how to deploy mRNA across a range of infectious diseases and other conditions, BioNTech wants to use mRNA to tackle cancer, working in combination with other therapies. Şahin and Türeci believe the best hopes of a cure will come from combining different treatments, including cell therapies, antibodies and other ways of modulating the immune system.
然而,与美国竞争对手莫德纳(Moderna)专注于如何将mRNA应用于一系列传染病和其他疾病不同,BioNTech希望将mRNA与其他疗法结合起来,用于治疗癌症。沙欣和图雷西认为,治愈的最大希望来自于结合不同的治疗方法,包括细胞疗法、抗体和其他调节免疫系统的方法。
Uğur Şahin: ‘We had this idea to develop technologies dedicated to really saving every single individual patient’
乌尔·沙欣:“我们有这样的想法,即致力于开发真正拯救每一个病人的技术。
Before the pandemic, the company was a little known player in the $1.2tn global pharmaceuticals market that is dominated by long-established companies pursuing many disease areas at once. In its 2019 initial public offering, BioNTech struggled to get investors excited, raising just $150mn; two years later it had become the most promising biotech in Europe.
在疫情之前,该公司在1.2万亿美元的manbetx app苹果 制药市场上是一个鲜为人知的参与者,该市场由老牌公司主导,同时研究多个疾病领域。在2019年的首次公开发行(IPO)中,BioNTech难以让投资者兴奋起来,仅筹集了1.5亿美元;两年后,它已成为欧洲最有前途的生物技术公司。
Matthias Kromayer, a managing partner at MiG Capital, who was a founding investor in BioNTech, says when he invested he didn’t even believe in the potential of mRNA. He gave the baby BioNTech money because the founders seemed to understand how technology would change healthcare, he says. “BioNTech isn’t just a biotech company. It is a multi-tech company and has been from the beginning . . . Ugur is always thinking 10 years ahead.”
米格资本(MiG Capital)的管理合伙人、BioNTech的创始投资者马蒂亚斯•克罗梅尔(Matthias Kromayer)表示,他在投资时甚至不相信mRNA的潜力。他说,他给刚刚创办时的BioNTech投资,是因为创始人似乎明白技术将如何改变医疗保健。“BioNTech不仅仅是一家生物科技公司。它是一家多技术公司,从一开始就是这样…乌尔·沙欣总是考虑未来10年。”
In April, BioNTech unveiled results of a study that combined mRNA with CAR-T-cell therapy to reprogramme a patient’s immune system. CAR-T is a complex treatment that involves collecting and modifying a patient’s immune cells to fight their cancer. So far, it has only worked in blood cancers. But BioNTech scientists created an mRNA booster that expanded the number of immune cells and improved their ability to kill a solid tumour, making it useful in a far larger range of cancers.
4月,BioNTech公布了一项研究结果,该研究将mRNA与CAR-T细胞疗法相结合,重新规划病人的免疫系统。CAR-T是一种复杂的治疗方法,包括收集和修改病人的免疫细胞来对抗他们的癌症。到目前为止,它只对血癌有效。但是BioNTech的科学家们创造了一种mRNA助推器,扩大了免疫细胞的数量,提高了它们杀死实体肿瘤的能力,使其对更多的癌症有用。
Brad Loncar, a biotech investor who runs a fund focused on cancer, declared it “borderline revolutionary”. “It is so interesting that it has the entire field rethinking how to go after solid tumours,” he says.
生物技术投资者布拉德·朗卡(Brad Loncar)管理着一个专注于癌症的基金,他宣称这是“边缘革命”。他说:“这是非常有趣的,它让整个领域重新思考如何治疗固体肿瘤。”
BioNTech’s strategy is to invest in many different technologies at once. Şahin uses the analogy of a smartphone that becomes more useful as you discover its many functions. “You understand it is not just a smartphone, it is a calculator, it allows you to do anything,” he said. “Based on the powerful platforms that we are developing, we believe that we will be able to provide a lot of different solutions for many diseases.”   
BioNTech的策略是同时投资多种不同的技术。沙欣使用了智能手机的比喻,当你发现它的许多功能时,它会变得更有用。他说:“你知道这不仅仅是一部智能手机,它还是一个计算器,它可以让你做任何事情。基于我们正在开发的强大平台,我们相信我们将能够为许多疾病提供许多不同的解决方案。”
Broadly speaking, the BioNTech founders see themselves as engineers of the immune system. Beyond cancer and infectious diseases, where the company continues to partner with Pfizer on vaccines, they also plan to tackle autoimmune conditions and regenerative medicine, which restores damaged or diseased cells. In total, the company is already running 19 early stage trials and 12 pre-clinical programmes.
一般来说,BioNTech的创始人认为自己是免疫系统的工程师。除了癌症和传染性疾病,该公司继续与辉瑞在疫苗方面进行合作,他们还计划解决自身免疫疾病和再生医学,即修复受损或患病细胞。总的来说,该公司已经在进行19个早期阶段试验和12个临床前项目。
Their newly bulging pockets permit such largesse, says one healthcare banker. A more cash-strapped company would have to be more selective and risk “throwing a great technology in the bin”. At the end of March, BioNTech’s assets were more than €19bn, surpassing even Moderna’s €16bn, and more than half that of large European pharma companies GlaxoSmithKline, AstraZeneca and Novartis.
一位医疗银行家表示,他们最近鼓鼓的口袋允许了这样的慷慨。一个资金更加紧张的公司将不得不更加挑剔,冒着“把一项伟大的技术扔进垃圾桶”的风险。3月底,BioNTech的资产超过190亿欧元,甚至超过了莫德纳的160亿欧元,超过了欧洲大型制药公司葛兰素史克(GlaxoSmithKline)、阿斯利康(AstraZeneca)和诺华(Novartis)的一半以上。
The BioNTech headquarters in Mainz in Germany. The company’s strategy is to invest in many different technologies at once
BioNTech总部位于德国美因茨。该公司的战略是同时投资多种不同的技术
Cancer trials are expensive, especially if a company has to first buy the drug it wishes to combine with its treatment. And personalised products such as CAR-T have proven difficult to market in a global healthcare system that is more familiar with buying drugs off the shelf such as consumer goods.
癌症试验是昂贵的,特别是如果一个公司必须首先购买它希望与治疗相结合的药物。像CAR-T这样的个性化产品已经被证明很难在manbetx app苹果 医疗体系中推广,因为manbetx app苹果 医疗体系更熟悉购买现成的药物,比如消费品。
With valuations of biotech companies dropping this year, Gareth Powell, a healthcare fund manager at Polar Capital, says BioNTech is lucky it can fund so many programmes. “If they didn’t have the Covid cash . . . I would imagine they would be under severe pressure,” he says. “The capital markets just wouldn’t be there for them to do this stuff.” 
极地资本(Polar Capital)的医疗保健基金经理加雷思•鲍威尔(Gareth Powell)表示,在今年生物科技板块的估值下降之际,BioNTech很幸运,它能资助这么多项目。“如果他们没有来自新冠疫苗的现金……我可以想象,他们会承受巨大的压力。资本市场不可能让他们做这些事情。”

‘Money doesn’t grow on trees’

“钱不是从树上长出来的”

Bryan Garnier & Co was part of a team of banks that helped take first Moderna and then BioNTech, public. Pierre Kiecolt-Wahl, co-head of equity capital markets at the French bank, says Moderna took a more incremental approach than BioNTech’s, focusing first on infectious diseases, where it hoped to show signs of success quickly that could persuade investors to put in more funds.
Bryan Garnier & Co是帮助莫德纳和BioNTech上市的银行团队的一员。这家法国银行股权资本市场联席主管皮埃尔•基科尔-瓦尔(Pierre Kiecolt-Wahl)表示,莫德纳采取了比BioNTech更循序渐进的做法,首先关注传染性疾病,希望在这方面迅速显示出成功迹象,从而说服投资者投入更多资金。
“Moderna knew money doesn’t grow on trees,” he says. By contrast, he says Şahin and Türeci were more confident that they had data to fight cancer.
“莫德纳知道钱不是从树上长出来的,”他说。他说,相比之下,沙欣和图雷西更自信地认为他们拥有对抗癌症的数据。
But even though it now has substantial financial resources, long-term success is not guaranteed. Loncar says it may yet turn out that mRNA doesn’t really work for cancer. “There’s a non-zero per cent chance that mRNA may completely strike out in cancer,” he says. “If that happens, BioNTech is going to feel it a lot harder than Moderna will.”
但是,即使它现在有大量的财政资源,长期的成功也不是板上钉钉的。朗卡说,mRNA仍有可能最终被证明对癌症真的不起作用。他说:“mRNA无法攻克癌症的可能性是有的。如果发生这种情况,BioNTech将比莫德纳更困难。”
Oncology is far trickier than creating vaccines — Tewari, the Jefferies analyst, describes it as “scientifically byzantine” — and it is a hypercompetitive field, with almost every major pharmaceutical company scouring for treatments for the same conditions.
肿瘤学比创造疫苗要棘手得多——杰富瑞公司的分析师特瓦里将其描述为“科学上神秘复杂”——而且它是一个竞争激烈的领域,几乎所有的主要制药公司都在为相同的病症寻找治疗方法。
BioNTech’s most advanced clinical oncology programme is for cancer vaccines. Unlike regular vaccines, they do not prevent the recipient from developing cancer, but are used as treatments to prompt the immune system to destroy mutated cells. In phase 2 trials, it has two FixVac programmes, where the vaccines are not personalised, and two where they are.
BioNTech最先进的临床肿瘤项目是癌症疫苗。与普通疫苗不同的是,它们不能防止受体患上癌症,而是用于治疗,促使免疫系统破坏突变细胞。在第二阶段试验中,它有两个疫苗不是个性化的FixVac项目,还有两个是个性化的。
Hopes for creating cancer vaccines have been dashed many times before. “It is a concept that has been around for decades. But there has been failure, after failure, after failure,” says Loncar.
研制癌症疫苗的希望以前已经破灭过很多次。“这是一个已经存在了几十年的概念。但失败一直在发生,一次又一次的失败,”朗卡说。
He says one problem could be that therapies are being deployed too late. New therapies are usually tried first in patients who have not responded to previous drugs and usually have later stage cancer, but he believes they might work better at an earlier stage, when the patient’s immune system is more robust.
他说,一个问题可能是治疗方法部署得太晚。新疗法通常首先在对以前的药物没有反应的病人身上尝试,而且通常是晚期癌症,但他认为这些疗法在早期阶段可能效果更好,因为此时病人的免疫系统更加强大。
Şahin counters that BioNTech has overcome a number of “critical hurdles” and that its early data shows its mRNA cancer vaccines are eliciting immune responses several hundred times stronger than were previously reported for conventional cancer vaccines.
沙欣反驳说,BioNTech已经克服了许多“关键障碍”,其早期数据显示,其mRNA癌症疫苗引发的免疫反应比以前报道的传统癌症疫苗强数百倍。
去年12月,法国-奥地利生物技术公司Valneva的一名生物学家进入奥地利维也纳的一个实验室,研究针对冠状病毒的灭活全病毒疫苗
The company is also doing trials in earlier stage cancers, and is particularly interested in giving the vaccines just after patients have had surgery to remove the primary tumour. In a phase 1 trial presented this month, the company showed positive results treating pancreatic cancer patients shortly after surgery.
该公司也在进行早期癌症的试验,尤其有兴趣在患者刚接受手术切除原发肿瘤后接种疫苗。在本月公布的一期试验中,该公司在治疗胰腺癌患者术后不久就取得了积极的结果。
But as well as the scientific uncertainty, BioNTech will face practical challenges as it tries to disrupt the pharmaceutical business. The company will have to push regulators to adapt to individualised therapies that break the mould of conventional clinical trials. While such trials usually take several years and lead to an approved product that never changes, the founders want to be able to update their medicines — like an iPhone —  as new data improves algorithms that predict the best way to target a tumour.
但是,除了科学上的不确定性,BioNTech在试图颠覆制药行业的过程中还将面临实际挑战。该公司将不得不推动监管机构适应打破传统临床试验模式的个性化治疗。虽然这样的试验通常需要数年时间,并最终获得一款永远不会改变的获批产品,但创始人希望能够更新他们的药物——就像iPhone一样——因为新数据改进了算法,可以预测瞄准肿瘤的最佳方式。
Türeci says the company has to take the “smallest steps” with “conservative” regulators whenever they enter new territory. “The problem with the way medicines are developed is that, at that time when you have something you can approve for patients and bring it to the market, the technology is already outdated [by] several years,” she says.
图雷西表示,无论何时进入新领域,该公司都必须对“保守”的监管机构采取“最小的步骤”。她说:“药物开发方式的问题是,当你有一种可以为患者批准并推向市场的药物时,这种技术已经过时好几年了。”

The ‘smallest steps’

“最小的步骤”

While BioNTech’s has no need to beg investors for more capital, the company will still have to navigate expectations of shareholders who bought it as a Covid stock. Shares in BioNTech have fallen by about 20 per cent in the past year, after some investors sold in anticipation that sales of the Covid vaccine would slow. But the stock is still up more than fourfold since March 2020, when the company first announced it was developing a shot with Pfizer.
虽然BioNTech没有必要乞求投资者提供更多资金,但该公司仍需应对作为新冠股票购买其股票的股东的预期。在一些投资者预期新冠疫苗的销售将放缓后,BioNTech的股价在过去一年下跌了约20%。但自2020年3月该公司首次宣布与辉瑞合作开发一种疫苗以来,其股价仍上涨了四倍多。
Loncar, the cancer-specialist investor, does not own BioNTech primarily because it still trades as a Covid stock. He believes shareholders may be in for a surprise. “Investors have been really spoiled by how quickly the Covid-19 vaccines succeeded and how well they did. That’s not normally how drug development goes,” he says. “One thing I worry about is they have a shareholder base today that expects them to succeed in non-Covid things tomorrow.”
癌症专家投资者朗卡没有持有BioNTech,主要是因为该公司仍作为新冠概念股交易。他认为,股东们可能会大吃一惊。“新冠疫苗成功得如此之快,表现得如此出色,投资者真的被宠坏了。药物开发通常不是这样的,”他说。“我担心的一件事是,他们今天的这些股东,会希望他们明天就在非新冠的项目上取得成功。”
Şahin tries to be sanguine about the company’s stock — he says he looks the price up about once a week, far less often than he checks medical journal sites. And he stresses that the company has always been clear with investors about its true vision: “We can’t guarantee to them what is going to happen in the next Covid season. This is more dependent on what’s happening in the world and how the virus is evolving, and less dependent on our competencies.”
沙欣试图对公司的股票持乐观态度——他说他大约每周查看一次股价,比他查看医学杂志网站的次数要少得多。他强调,该公司一直向投资者明确其真正的愿景:“我们不能向他们保证下一个新冠季节会发生什么。这更多地取决于世界上正在发生的事情以及病毒的进化方式,而不是依赖于我们的能力。”
Still he was surprised recently when the share price rose as investors anticipated the company would create a vaccine for monkeypox. (BioNTech has not started work on a jab for the spreading disease. Şahin says they are “preparing ourselves to be prepared” to do so, but it does not look like a global challenge yet.)
不过,最近他对公司股价上涨感到惊讶,因为投资者预计公司将研发出猴痘疫苗。(BioNTech还没有开始研究这种正在传播的疾病的疫苗。沙欣表示,他们正在“做很少的准备”,但这看起来还不像是一个manbetx app苹果 性的挑战。)
Some investors are asking whether BioNTech can handle quite so much cash — and take on so many challenges at once.
一些投资者质疑,BioNTech是否能够同时处理这么多现金,并接受这么多挑战。
(从左至右)今年2月,在BioNTech位于德国西部马尔堡的生产基地,谭德塞发表声明时,加纳总统纳纳·阿库福-阿多、德国manbetx20客户端下载 合作与发展部长斯尔文·舒尔茨、非洲疾病控制和预防中心主任约翰·恩肯加松、世卫组织总干事谭德塞·阿哈诺姆·盖布雷耶苏斯、卢旺达总统保罗·卡加梅、BioNTech首席执行官乌尔·沙欣、塞内加尔和非洲联盟主席麦基·萨勒
While the company has decided to use the vast majority of its vaccine proceeds for internal investment, with just a couple of small bolt-on acquisitions, it did announce plans to return almost €2bn to shareholders in a buyback and dividend. This also divided shareholder opinion, because it is so unusual for a biotech with many programmes in early stage development to cough up cash. “It was a terrible idea,” says Powell at Polar Capital. “It’s such a waste of money.” 
尽管该公司已决定将其绝大部分疫苗收益用于内部投资(仅进行了几笔小型补强性收购),但它确实宣布了以回购和股息的方式向股东返还近20亿欧元的计划。这也引起了股东们的意见分歧,因为对于一个有许多项目处于早期开发阶段的生物技术公司来说,把钱送还给股东是非常不寻常的。极地资本的鲍威尔表示:“这是一个糟糕的想法。这太浪费钱了。”
But analysts say that most long-term investors trust the founders who delivered the Covid vaccine at such scale and speed. Van Voorthuizen at Kempen says they are particularly “diligent” about structuring their trials so that they give solid answers to specific questions. “They will stop [a trial] if it doesn’t work. They are not depending on one or other programmes to make or break the company,” she says.
但分析人士表示,大多数长期投资者都信任以如此规模和速度推出新冠疫苗的创始人。Kempen的范•沃特伊森说,他们特别“勤奋”地组织他们的试验,以便对特定的问题给出可靠的答案。“如果(试验)不起作用,他们就会停止。他们不会依赖于一个或几个项目来成就或摧毁公司,”她表示。
The healthcare banker believes BioNTech is “by far the most exciting biotech in Europe”, adding that there are no founders more inspirational than Şahin and Türeci. “They are so insanely smart and they work so damn hard,” he says.
前文提到的那位医疗行业银行家认为,BioNTech是“迄今为止欧洲最令人兴奋的生物科技公司”,他补充称,没有哪家公司的创始人比沙欣和图雷西更鼓舞人心。“他们非常聪明,工作非常努力,”他说。
Türeci describes how Şahin can suck up information, rapidly reading dozens of papers on a new condition. “It’s sort of something like machine learning what he does,” she jokes. “In a weekend, the entire history of science on this specific topic.” 
图雷西描述了沙欣如何吸收信息,快速阅读几十篇关于新状况的论文。“他的这种方式这有点像机器学习,”她开玩笑说。“在一个周末,他会看完一个特定的话题的整个科学史。”
Governments from around the world are calling for advice for birthing their own versions of BioNTech, Türeci says. But, just as the company surprised the world in 2020 by navigating the uncharted waters of mRNA vaccine development, Türeci says they are once again heading into “unknown territory”. And this time, success is not likely to happen at lightspeed.  
图雷西说,世界各地的政府都在请教他们,如何才能在他们自己的国家孕育出BioNTech这样的公司。但是,正如该公司在2020年通过驾驭mRNA疫苗开发的未知领域而令世界惊讶一样,图雷西说他们正再次进入“未知领域”。而这一次,成功不大可能会迅速到来。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

会计师事务所对美国资格考核改革提出担忧

代表“四大”的机构CAQ批评称,改革美国会计师资格规则的计划可能会使公司面临歧视诉讼,并增加入行障碍。

特朗普和海湖庄园的力量

这位前房地产开发商非常了解如何将建筑和空间有效地用作宣传。

为2024年的世界感到高兴的十个理由

从巴黎圣母院的修复到《抑制热情》的大结局,这一年其实并不算太糟。

2025年德国大选:主要的竞选承诺是什么?

各大政党提出了截然不同的计划,以重振欧洲最大manbetx20客户端下载 体的命运。

“市场恐慌”:巴西财政赤字导致货币跌至新低

总统在面临其第三个任期内的最大挑战。

特朗普过渡团队寻求在“第一天”让美国退出世卫组织

美国的迅速退出将使manbetx app苹果 卫生机构失去主要资金来源,并削弱其应对紧急情况的能力。
设置字号×
最小
较小
默认
较大
最大
分享×